Human mesenchymal stem cells alter the gene profile of monocytes from patients with Type 2 diabetes and end-stage renal disease

Andrea F Wise, Timothy M Williams, Stephen A Rudd, Christine A Wells, Peter G Kerr, Sharon D Ricardo

Research output: Contribution to journalArticleResearchpeer-review

Abstract

AIM: Macrophage infiltration contributes to the pathogenesis of Type 2 diabetes. Mesenchymal stem cells (MSCs) possess immunomodulatory properties, making them an ideal candidate for therapeutic intervention. This study investigated whether MSCs can modulate the phenotype of monocytes isolated from Type 2 diabetic patients with end-stage renal disease. MATERIALS METHODS: Monocytes from control (n = 4) and Type 2 diabetic patients with end-stage renal disease (n = 5) were assessed using flow cytometry and microarray profiling, following 48 h of co-culture with MSCs. RESULTS: Control subjects had a greater proportion of CD14++CD16- monocytes while diabetic patients had a higher proportion of CD14++CD16+ and CD14+CD16++ monocytes. MSCs promoted the proliferation of monocytes isolated from diabetic patients, reduced HLA-DR expression in both groups and promoted the expression of anti-inflammatory genes. CONCLUSION: MSC-derived factors alter the polarization of monocytes isolated from healthy and diabetic subjects toward an M2 phenotype.
Original languageEnglish
Pages (from-to)145-158
Number of pages14
JournalRegenerative Medicine
Volume11
Issue number2
DOIs
Publication statusPublished - 2 Mar 2016

Keywords

  • end-stage renal disease
  • macrophages
  • mesenchymal stem cells
  • monocytes
  • Type 2 diabetes

Cite this

@article{5a5cc3895191494aab7012dcba9a0f05,
title = "Human mesenchymal stem cells alter the gene profile of monocytes from patients with Type 2 diabetes and end-stage renal disease",
abstract = "AIM: Macrophage infiltration contributes to the pathogenesis of Type 2 diabetes. Mesenchymal stem cells (MSCs) possess immunomodulatory properties, making them an ideal candidate for therapeutic intervention. This study investigated whether MSCs can modulate the phenotype of monocytes isolated from Type 2 diabetic patients with end-stage renal disease. MATERIALS METHODS: Monocytes from control (n = 4) and Type 2 diabetic patients with end-stage renal disease (n = 5) were assessed using flow cytometry and microarray profiling, following 48 h of co-culture with MSCs. RESULTS: Control subjects had a greater proportion of CD14++CD16- monocytes while diabetic patients had a higher proportion of CD14++CD16+ and CD14+CD16++ monocytes. MSCs promoted the proliferation of monocytes isolated from diabetic patients, reduced HLA-DR expression in both groups and promoted the expression of anti-inflammatory genes. CONCLUSION: MSC-derived factors alter the polarization of monocytes isolated from healthy and diabetic subjects toward an M2 phenotype.",
keywords = "end-stage renal disease, macrophages, mesenchymal stem cells, monocytes, Type 2 diabetes",
author = "Wise, {Andrea F} and Williams, {Timothy M} and Rudd, {Stephen A} and Wells, {Christine A} and Kerr, {Peter G} and Ricardo, {Sharon D}",
year = "2016",
month = "3",
day = "2",
doi = "10.2217/rme.15.74",
language = "English",
volume = "11",
pages = "145--158",
journal = "Regenerative Medicine",
issn = "1746-0751",
publisher = "Future Medicine Ltd",
number = "2",

}

Human mesenchymal stem cells alter the gene profile of monocytes from patients with Type 2 diabetes and end-stage renal disease. / Wise, Andrea F; Williams, Timothy M; Rudd, Stephen A; Wells, Christine A; Kerr, Peter G; Ricardo, Sharon D.

In: Regenerative Medicine, Vol. 11, No. 2, 02.03.2016, p. 145-158.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Human mesenchymal stem cells alter the gene profile of monocytes from patients with Type 2 diabetes and end-stage renal disease

AU - Wise, Andrea F

AU - Williams, Timothy M

AU - Rudd, Stephen A

AU - Wells, Christine A

AU - Kerr, Peter G

AU - Ricardo, Sharon D

PY - 2016/3/2

Y1 - 2016/3/2

N2 - AIM: Macrophage infiltration contributes to the pathogenesis of Type 2 diabetes. Mesenchymal stem cells (MSCs) possess immunomodulatory properties, making them an ideal candidate for therapeutic intervention. This study investigated whether MSCs can modulate the phenotype of monocytes isolated from Type 2 diabetic patients with end-stage renal disease. MATERIALS METHODS: Monocytes from control (n = 4) and Type 2 diabetic patients with end-stage renal disease (n = 5) were assessed using flow cytometry and microarray profiling, following 48 h of co-culture with MSCs. RESULTS: Control subjects had a greater proportion of CD14++CD16- monocytes while diabetic patients had a higher proportion of CD14++CD16+ and CD14+CD16++ monocytes. MSCs promoted the proliferation of monocytes isolated from diabetic patients, reduced HLA-DR expression in both groups and promoted the expression of anti-inflammatory genes. CONCLUSION: MSC-derived factors alter the polarization of monocytes isolated from healthy and diabetic subjects toward an M2 phenotype.

AB - AIM: Macrophage infiltration contributes to the pathogenesis of Type 2 diabetes. Mesenchymal stem cells (MSCs) possess immunomodulatory properties, making them an ideal candidate for therapeutic intervention. This study investigated whether MSCs can modulate the phenotype of monocytes isolated from Type 2 diabetic patients with end-stage renal disease. MATERIALS METHODS: Monocytes from control (n = 4) and Type 2 diabetic patients with end-stage renal disease (n = 5) were assessed using flow cytometry and microarray profiling, following 48 h of co-culture with MSCs. RESULTS: Control subjects had a greater proportion of CD14++CD16- monocytes while diabetic patients had a higher proportion of CD14++CD16+ and CD14+CD16++ monocytes. MSCs promoted the proliferation of monocytes isolated from diabetic patients, reduced HLA-DR expression in both groups and promoted the expression of anti-inflammatory genes. CONCLUSION: MSC-derived factors alter the polarization of monocytes isolated from healthy and diabetic subjects toward an M2 phenotype.

KW - end-stage renal disease

KW - macrophages

KW - mesenchymal stem cells

KW - monocytes

KW - Type 2 diabetes

U2 - 10.2217/rme.15.74

DO - 10.2217/rme.15.74

M3 - Article

VL - 11

SP - 145

EP - 158

JO - Regenerative Medicine

JF - Regenerative Medicine

SN - 1746-0751

IS - 2

ER -